Steady progress with experimental gene therapies gave investors reasons to cheer.
News & Analysis: uniQure
Good news has a way of attracting suitors.
Roche's big step into the gene-editing space will spark interest for these two stocks.
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.
Great clinical results for its experimental hemophilia B gene therapy lit a fire beneath this biotech stock.
Is continued success in the cards for these biotech stocks?
Two e-commerce specialists head up this list of promising investment ideas.
These two clinical-stage biotechs could be absolute steals at current levels.
Investors are cheering the FDA's surprisingly progressive take on uniQure's novel hemophilia B gene therapy candidate.
UniQure N.V.'s stock rose on Thursday on the back of positive clinical news.